4147 |
Ongoing TAVR Trials and Updating TAVR Guidelines |
Eberhard Grube |
Apr. 25. 17 |
4146 |
Atrial Fibrillation & Antithrombotic Regimens: Finding the \"Sweet-Spot\" from RCTs |
Freek W.A. Verheugt |
Apr. 25. 17 |
4145 |
Bioresorbable Vascular Scaffolds and DAPT Duration: The Longer the Better? |
David Joel Cohen |
Apr. 25. 17 |
4144 |
Ad Hoc Versus Staged PCI for Multivessel Disease: Safety First, Choose Wisely! |
Neal S. Kleiman |
Apr. 25. 17 |
4143 |
[Debate II: How to Find Ischemia?] iFR Can Be a Gold Standard. |
Justin E. Davies |
Apr. 25. 17 |
4142 |
[Debate II: How to Find Ischemia?] FFR Is a Gold Standard. |
Nils Johnson |
Apr. 25. 17 |
4141 |
Routine Assessment of the Microcirculation and Absolute Flow: A Glimpse to the Future |
William F. Fearon |
Apr. 25. 17 |
4140 |
Clinical Outcome of DEFER |
Jung-Min Ahn |
Apr. 25. 17 |
4139 |
FFR, iFR, Contrast FFR, CFR, IMR: Two Many Indexes, Please Make Them Simple! |
Nico Pijls |
Apr. 25. 17 |
4138 |
[Debate I: How to Do PCI?] QCA-Guidance Is Enough. |
Cheol Whan Lee |
Apr. 25. 17 |